The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
In a move that ends uncertainty regarding its listing status, Akanda Corp. announced it has regained full compliance with Nasdaq's periodic reporting requirements. This development follows the company's filing of its Annual Report on Form 20-F for fiscal year 2025, effectively resolving the non-compliance matter that originated on May 20, 2026. The company received formal written confirmation from Nasdaq on June 10, 2026, verifying that the deficiency has been cured.
This regulatory breakthrough comes at a critical time for the medical cannabis sector, where small-cap firms face mounting pressure to maintain strict governance and transparency standards. Compared to industry peers, Akanda has struggled with administrative delays in financial disclosures, but regaining compliance signals a stabilization of its internal controls. Per market data, avoiding a delisting is a vital step for maintaining stock liquidity and ensuring continued access to global capital markets.
Sign in to access this content
Sign InInvestors should watch for price stability at current levels, as AKAN closed at $15.39 (close June 11, 2026), hitting a session high of $15.39. While the upcoming economic calendar shows no immediate catalysts specifically for the company, the primary focus remains on future quarterly filings to ensure Akanda maintains its standing and avoids further regulatory scrutiny from Nasdaq.